Search

Relief Therapeutics Holding Sa filed a Form 6-K with the U.S. Securities and Exchange Commission on October 28, 2024. This filing is used by certain foreign private issuers to provide information required to be made public in their home country or distributed to shareholders. The SEC filing is a formal document or financial statement submitted by publicly-traded companies. [Extracted from the article]

Mustang Bio, Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission on October 25, 2024. This form is used to report material events or corporate changes that are important to investors. The filing provides current information on specific events and is a formal document submitted by publicly-traded companies. The company's contact information is located in Worcester, MA, and the SEC file number is 0001104659-24-111500. [Extracted from the article]

Moleculin Biotech, Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission on October 25, 2024. This filing is a "current report" used to disclose material events or corporate changes important to investors. The company's contact information is provided, and the filing can be accessed on the SEC's website. The document pertains to biopharmaceutical and healthcare biotechnology companies, with a focus on business and SEC filings. [Extracted from the article]

Day One Biopharmaceuticals, Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission on October 30, 2024. This form is used to report material events or corporate changes important to investors. The company's contact information is located in Brisbane, CA, and the filing can be accessed on the SEC's website for further details. The filing pertains to the pharmaceutical industry and provides current information on specific events. [Extracted from the article]

Viatris Inc. filed a U.S. Securities and Exchange Commission (SEC) Form ARS, an annual report to security holders, on October 25, 2024. The company's SIC code is 2834, Pharmaceutical Preparations, and the SEC file number is 0001193125-24-244177. This filing is a formal document submitted to the SEC by publicly-traded companies, providing information to security holders. For more details, the full SEC filing can be accessed at https://www.sec.gov/Archives/edgar/data/1792044/0001193125-24-244177-index.html. [Extracted from the article]

Vtv Therapeutics Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission on October 25, 2024. This form is used to report material events or corporate changes important to investors. The company's SIC code is 2834, and the filing can be accessed on the SEC's website. The document provides current information on specific events for publicly-traded companies in the pharmaceutical industry. [Extracted from the article]

Skye Bioscience, Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission on October 29, 2024. This form is used to report material events or corporate changes that are important to investors. The company's SIC code is 2834, Pharmaceutical Preparations, and the filing can be accessed on the SEC's website. For more information, visit https://www.sec.gov/Archives/edgar/data/1516551/0001516551-24-000093-index.html. [Extracted from the article]

Cormedix Inc. recently filed a Form 8-K with the U.S. Securities and Exchange Commission on October 30, 2024. This filing is a "current report" used to disclose material events or corporate changes important to investors. Cormedix Inc. is classified under SIC code 2834 for Pharmaceutical Preparations, and the company's contact information is located in Berkeley Heights, NJ. The SEC filing can be accessed for further details on the company's activities. [Extracted from the article]

Macrogenics Inc., a healthcare biotechnology company, filed a U.S. Securities and Exchange Commission (SEC) Form 8-K on October 30, 2024. This form is used to report material events or corporate changes that are important to investors and have not been previously reported. The SEC filing provides current information on specific events and can be accessed on the SEC website. The company's contact information is located in Rockville, MD. [Extracted from the article]

Incannex Healthcare Inc. filed a U.S. Securities and Exchange Commission (SEC) Form 8-K on October 24, 2024, with the SIC code for the company being 2834, Pharmaceutical Preparations. The filing included 14 documents and provided contact information for the company located in Victoria, Australia. Form 8-K is used to report material events or corporate changes important to investors, offering more current information than Forms 10-Q or 10-K. This SEC filing is a formal document submitted by publicly-traded companies, and more information can be found on the SEC website. [Extracted from the article]

Dr Reddys Laboratories Ltd filed a Form 6-K with the U.S. Securities and Exchange Commission on October 29, 2024. This filing is used by certain foreign private issuers to provide information required to be made public in their home country or distributed to shareholders. The SEC filing contains contact information for the company and is not considered a formal filing for Section 18 liability purposes. More information on this filing can be found on the SEC's website. [Extracted from the article]

Aquestive Therapeutics, Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission on October 25, 2024. This form is used to report material events or corporate changes important to investors. The company's SIC code is 2834, and the SEC file number is 0001628280-24-043761. The filing provides current information on specific events and can be accessed on the SEC's website for further details. [Extracted from the article]

Pharming Group N.V. filed a Form 6-K with the U.S. Securities and Exchange Commission on October 24, 2024. This filing is used by certain foreign private issuers to provide information required to be made public in their home country or distributed to shareholders. The SEC filing is a formal document submitted by publicly-traded companies, and more information can be found on the SEC's website. [Extracted from the article]

Cadrenal Therapeutics, Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission on October 24, 2024. This form is used to report material events or corporate changes important to investors. The company's SIC code is 2834, Pharmaceutical Preparations, and the filing includes 14 documents. For more information, the SEC filing can be accessed at the provided link. [Extracted from the article]

Lexaria Bioscience Corp. recently filed a Form 8-K with the U.S. Securities and Exchange Commission on October 18, 2024. This filing is a "current report" used to disclose material events or corporate changes important to investors. The company's SIC code is 2834, Pharmaceutical Preparations, and the filing can be accessed on the SEC's website for further information. [Extracted from the article]

Lumos Pharma, Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission on October 23, 2024. This form is used to report material events or corporate changes important to investors. The company's contact information is located in Austin, Texas, and the filing can be accessed on the SEC's website for further details. The document falls under the SIC code 2834 for Pharmaceutical Preparations, and it contains 19 related documents. [Extracted from the article]

Canopy Growth Corp. filed a U.S. Securities and Exchange Commission (SEC) Form 8-K on October 17, 2024, with 15 documents included. The filing is a "current report" used to disclose material events or corporate changes important to investors. This formal document provides more current information than Forms 10-Q or 10-K and can be accessed on the SEC website. [Extracted from the article]

Kezar Life Sciences, Inc. filed a U.S. Securities and Exchange Commission (SEC) Form 8-K on October 17, 2024, with the SIC code for the company being 2834, Pharmaceutical Preparations. The filing, which included 19 documents, is a "current report" used to disclose material events or corporate changes important to investors. This formal document provides more current information than Forms 10-Q or 10-K and can be accessed on the SEC website for further details. [Extracted from the article]

Avadel Pharmaceuticals Plc filed a Form 8-K with the U.S. Securities and Exchange Commission on October 17, 2024. This form is used to report material events or corporate changes that are important to investors and have not been previously reported. The filing provides current information on specific events and is a formal document submitted by publicly-traded companies. [Extracted from the article]

The article discusses a recent SEC filing by 180 Life Sciences Corp., a company in the pharmaceutical preparations industry. The filing, known as Form 8-K, is used to report material events or corporate changes that are important to investors. This document provides current information on specific events and is submitted to the U.S. Securities and Exchange Commission by publicly-traded companies. The article emphasizes the significance of this filing for investors and security holders. [Extracted from the article]

Elicio Therapeutics, Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission on October 17, 2024. This filing is a "current report" used to disclose material events or corporate changes important to investors. The company's SIC code is 2834, Pharmaceutical Preparations, and the filing includes contact information for Elicio Therapeutics, Inc. located in Boston, MA. The SEC filing provides up-to-date information on specific events and can be accessed on the SEC website for further details. [Extracted from the article]

Revelation Biosciences, Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission on October 21, 2024. The filing, related to pharmaceutical preparations, included 11 documents and provided contact information for the company based in San Diego, CA. Form 8-K is used to report material events or corporate changes that are important to investors, offering more current information than Forms 10-Q or 10-K. This SEC filing is a formal document submitted by publicly-traded companies, and more details can be found on the SEC website. [Extracted from the article]

Orgenesis Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission on October 23, 2024, as reported by NewsRx journalists in Washington, D.C. The filing pertains to material events or corporate changes important to investors. This document provides current information on specified events for publicly-traded companies like Orgenesis Inc., which operates in the pharmaceutical preparations sector. For more details, the SEC filing can be accessed at the provided link. [Extracted from the article]

Moleculin Biotech, Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission on October 17, 2024. This form is used to report material events or corporate changes important to investors. The company's contact information is located in Houston, Texas, and the filing can be accessed on the SEC's website. The document pertains to biopharmaceutical and healthcare biotechnology companies, falling under the SIC code 2834 for Pharmaceutical Preparations. [Extracted from the article]

Lipocine Inc. recently filed a Form 8-K with the U.S. Securities and Exchange Commission (SEC) on October 22, 2024. This form is used to report material events or corporate changes that are important to investors and have not been previously reported. The filing provides current information on specific events and is a formal document submitted by publicly-traded companies. Lipocine Inc. is a pharmaceutical company based in Salt Lake City, with the SEC file number 0001493152-24-042117. [Extracted from the article]

Eloxx Pharmaceuticals, Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission on October 17, 2024. This form is used to report material events or corporate changes that are important to investors. The filing provides current information on specific events and is a formal document submitted by publicly-traded companies. The company's contact information is listed as 480 Arsenal Way, Suite 130, Watertown, MA 02472, with a phone number of 781-577-5300. [Extracted from the article]

Xortx Therapeutics Inc. filed a Form 6-K with the U.S. Securities and Exchange Commission on October 17, 2024. This filing is used by certain foreign private issuers to provide information required to be made public in their home country or distributed to shareholders. The SEC filing is a formal document submitted by publicly-traded companies, and more information can be found on the SEC website. The company's SIC code is 2834, Pharmaceutical Preparations, and their contact information is located in Vancouver. [Extracted from the article]

The article discusses a recent SEC filing by Tiziana Life Sciences Ltd, a biotechnology company based in London, England. The filing, known as Form 6-K, is used by foreign private issuers to provide required information to the public, foreign stock exchanges, or security holders. This formal document is not considered "filed" for Section 18 liability purposes and serves as the primary means of communication between annual reports for foreign private issuers. The SEC filing can be accessed for further information on the company's activities. [Extracted from the article]

Revance Therapeutics, Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission on October 18, 2024. This form is used to report material events or corporate changes that are important to investors. The filing provides current information on specific events and is a formal document submitted by publicly-traded companies. The company's contact information is located in Nashville, Tennessee, and the filing can be accessed on the SEC's website for further details. [Extracted from the article]

Prophase Labs, Inc. filed a U.S. Securities and Exchange Commission (SEC) Form 8-K on October 18, 2024, with 13 documents attached. The company's SIC code is 2834, Pharmaceutical Preparations, and its contact information is located in Garden City, New York. The Form 8-K is a current report used to disclose material events or corporate changes important to investors, providing more up-to-date information than Forms 10-Q or 10-K. This SEC filing is a formal document submitted by publicly-traded companies, and more details can be found on the SEC's website. [Extracted from the article]

Petiq, Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission on October 22, 2024. The filing pertains to material events or corporate changes important to investors. This document provides current information on specified events for publicly-traded companies. The SEC filing can be accessed for further details at the provided link. [Extracted from the article]

Incannex Healthcare Inc. filed a U.S. Securities and Exchange Commission (SEC) Form 8-K on October 21, 2024, with the SIC code for the company being 2834, Pharmaceutical Preparations. The filing included 15 documents and provided contact information for the company. Form 8-K is used to report material events or corporate changes important to investors, offering more current information than Forms 10-Q or 10-K. This SEC filing is a formal document submitted by publicly-traded companies, and more information can be found on the SEC website. [Extracted from the article]

Alterity Therapeutics Ltd filed a Form 6-K with the U.S. Securities and Exchange Commission on October 23, 2024. This filing is used by certain foreign private issuers to provide information required to be made public in their home country or distributed to shareholders. The SEC filing contains contact information for the company and details about the purpose of Form 6-K. The document is not considered "filed" for Section 18 liability purposes. [Extracted from the article]

Orgenesis Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission on October 17, 2024, as reported by NewsRx journalists in Washington, D.C. The filing pertains to material events or corporate changes important to investors. This document provides current information on specified events for publicly-traded companies like Orgenesis Inc., which operates in the pharmaceutical preparations sector. More details can be found on the SEC's website. [Extracted from the article]

Calidi Biotherapeutics, Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission on October 18, 2024. This form is used to report material events or corporate changes important to investors. The filing provides current information on specified events for publicly-traded companies like Calidi Biotherapeutics, Inc. The company's contact information is located in San Diego, California. [Extracted from the article]

Galmed Pharmaceuticals Ltd. filed a Form 6-K with the U.S. Securities and Exchange Commission on October 15, 2024. This filing is used by certain foreign private issuers to provide information required to be made public in their domicile country or distributed to security holders. The SEC filing is a formal document submitted by publicly-traded companies, and more information can be found on the SEC website. The company's SIC code is 2834, Pharmaceutical Preparations, and their contact information is located in Ramat Gan, Israel. [Extracted from the article]

Iterum Therapeutics Plc filed a Form 8-K with the U.S. Securities and Exchange Commission on October 15, 2024. This form is used to report material events or corporate changes important to investors. The company's contact information is located in Dublin, and the filing can be accessed on the SEC's website. This news article focuses on pharmaceutical companies, business, SEC filings, drugs and therapies, and health and medicine. [Extracted from the article]

Scienture Holdings, Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission on October 11, 2024. The filing, related to pharmaceutical preparations, included 13 documents and can be accessed on the SEC website. Form 8-K is used to report material events or corporate changes that are important to investors and provides more current information than Forms 10-Q or 10-K. For more details, the SEC filing can be found at the provided link. [Extracted from the article]

Ars Pharmaceuticals, Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission on October 15, 2024. The filing contains information about material events or corporate changes that are important to investors. The company's contact information is located in San Diego, California, and the filing can be accessed on the SEC's website for further details. [Extracted from the article]

Cingulate Inc. recently filed a Form 8-K with the U.S. Securities and Exchange Commission on October 15, 2024. The filing, related to pharmaceutical preparations, included 16 documents and can be accessed through the SEC website. Form 8-K is used to report material events or corporate changes that are important to investors, providing more current information than Forms 10-Q or 10-K. For more details, the SEC filing can be found at the provided link. [Extracted from the article]

Allakos Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission on October 10, 2024. This form is used to report material events or corporate changes that are important to investors and have not been previously reported. The filing provides more current information than Forms 10-Q or 10-K and is a formal document submitted by publicly-traded companies. The company's contact information is located in San Carlos, CA, and the SEC file number is 0000950170-24-114047. [Extracted from the article]

Purple Biotech Ltd., a biotechnology company, filed a Form 6-K with the U.S. Securities and Exchange Commission on October 10, 2024. This filing is used by certain foreign private issuers to provide information required to be made public in their home country or distributed to shareholders. The SEC filing is a formal document submitted by publicly-traded companies and can be accessed for more information on the SEC website. [Extracted from the article]

Theratechnologies Inc., a biopharmaceutical company, filed a Form 6-K with the U.S. Securities and Exchange Commission on October 10, 2024. This filing is a formal document submitted by publicly-traded companies to provide information required to be made public in their domicile country. The SEC file number for Theratechnologies Inc. is 0001193125-24-235639, and the company's contact information is located in Montreal. This report is essential for foreign private issuers to furnish information to the public between annual reports, as they are not required to file on Forms 10-Q or 8-K. [Extracted from the article]

Sigyn Therapeutics, Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission on October 16, 2024. This form is used to report material events or corporate changes that are important to investors. The company's SIC code is 3841, and the filing contains 13 documents. For more information, the SEC filing can be accessed at the provided link. [Extracted from the article]

Elanco Animal Health Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission on October 16, 2024. This form is used to report material events or corporate changes important to investors. The filing provides current information on specific events and is a formal document submitted by publicly-traded companies. The SEC file number for Elanco Animal Health Inc. is 0001104659-24-108914, and more details can be found on the SEC website. [Extracted from the article]

Cocrystal Pharma, Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission on October 10, 2024. This form is used to report material events or corporate changes that are important to investors and have not been previously reported. The filing provides current information on specific events and is a formal document submitted by publicly-traded companies. The company's contact information is located in Bothell, WA, and the filing can be accessed on the SEC's website for further details. [Extracted from the article]

Redhill Biopharma Ltd. filed a Form 6-K with the U.S. Securities and Exchange Commission on October 15, 2024. This filing is used by certain foreign private issuers to provide information required to be made public in their home country or distributed to shareholders. The SEC filing is a formal document submitted by publicly-traded companies, and more information can be found on the SEC's website. The company is located in Tel Aviv, and the filing pertains to pharmaceutical preparations. [Extracted from the article]

The article discusses a recent SEC filing by Gsk Plc, a pharmaceutical company based in London. The filing, known as Form 6-K, is used by foreign private issuers to provide information required to be made public in their home country or stock exchange. This filing is not considered "filed" for Section 18 liability purposes and serves as a way for foreign private issuers to communicate with shareholders between annual reports. The document provides contact information for Gsk Plc and can be accessed on the SEC's website for further details. [Extracted from the article]

Genmab A, a pharmaceutical company, filed a Form 6-K with the U.S. Securities and Exchange Commission on October 15, 2024. This filing is used by certain foreign private issuers to provide information required to be made public in their home country or distributed to shareholders. The SEC filing is a formal document submitted by publicly-traded companies and can be accessed for more information on the SEC website. [Extracted from the article]

Carisma Therapeutics Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission on October 11, 2024. This form is used to report material events or corporate changes important to investors. The company's contact information is located in Philadelphia, PA, and the filing can be accessed on the SEC's website. The filing pertains to the pharmaceutical preparations industry, and more information can be found on the SEC's website. [Extracted from the article]